The Archer® FusionPlex® Lung Kit is a targeted next-generation sequencing (NGS) assay to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The kit is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.
Lung Cancer
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FGFR (Fibroblast Growth Factor Receptor), MET (MET proto-oncogene, receptor tyrosine kinase), NRG1 (Neuregulin 1)
See More ...
Next generation sequencing (NGS)